Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation [PDF]
, 2017 Current antiretroviral therapy (ART) for HIV/AIDS slows disease progression by reducing viral loads and increasing CD4 counts. Yet ART is not curative due to the persistence of CD4+ T-cell proviral reservoirs that chronically resupply active virus ...
Albert, Brice J +8 more
core +2 more sources
Frontiers in Immunology, 2018 Histone deacetylases (HDAC) are one of the key epigenetic modifiers that control chromatin accessibility and gene expression. Their role in tumorigenesis is well established and HDAC inhibitors have emerged as an effective treatment modality.
Sajad A. Bhat +5 more
doaj +1 more source
HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
Protein & Cell, 2020 Immunotherapy has been applied successfully to treat B-cell lymphomas in preclinical models or clinical settings. However, immunotherapy resistance is a major challenge for B-cell lymphoma treatment.
Xiaoguang Wang +5 more
doaj +1 more source
Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression
Signal Transduction and Targeted Therapy, 2023 Histone deacetylase (HDAC) is a kind of protease that modifies histone to regulate gene expression, and is usually abnormally activated in tumors. The approved pan-HDAC inhibitors have demonstrated clinical benefits for patients in some hematologic ...
Zonglong Hu +7 more
doaj +1 more source
Frontiers in Immunology, 2023 Breast cancer is one of the common malignancies with poor prognosis worldwide. The treatment of breast cancer patients includes surgery, radiation, hormone therapy, chemotherapy, targeted drug therapy and immunotherapy. In recent years, immunotherapy has
Bi Lian, Xiaosong Chen, Kunwei Shen
doaj +1 more source
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]
, 2016 Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S. +17 more
core +2 more sources
Journal of Translational Medicine, 2020 It is well established that thymidylate synthase inhibitors can cause cellular toxicity through uracil DNA glycosylase (UNG2)-dependent pathways. Additionally, thymidylate synthase inhibitors and HDAC inhibitors are known to act synergistically in a ...
Meredith S. Showler, Brian P. Weiser
doaj +1 more source
Histone deacetylase adaptation in single ventricle heart disease and a young animal model of right ventricular hypertrophy. [PDF]
, 2017 BackgroundHistone deacetylase (HDAC) inhibitors are promising therapeutics for various forms of cardiac diseases. The purpose of this study was to assess cardiac HDAC catalytic activity and expression in children with single ventricle (SV) heart disease ...
A Cevik +49 more
core +1 more source
Epigenetics in Friedreich's ataxia: Challenges and opportunities for therapy [PDF]
, 2013 Copyright © 2013 Chiranjeevi Sandi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly ...
Al-Mahdawi, S, Pook, MA, Sandi, C
core +2 more sources
HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma [PDF]
, 2016 Indexación: Web of ScienceBackground: Class I histone deacetylases (HDACs) have been reported to be overexpressed in clear cell renal cell carcinoma (ccRCC), whereas the expression of class II HDACs is unknown.
Attwood, Kris +14 more
core +2 more sources